International Psoriasis Council

subscribe
Search

Advancing Knowledge. Enhancing Care.

subscribe
Search

Advancing Knowledge. Enhancing Care.

PsoProtect Registry Data Update

psoprotect_update_615

PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes the first 1,652 cases. Below is a summary of the data collected or view the full report on the PsoProtect website.

Average age: 48 years
Phenotype of psoriasis: 1,605 plaque psoriasis, 47 pustular psoriasis
Average BMI: 27.7 kg/m2
Average number of days of symptoms from COVID-19: 10 days

Cases reported by country of assessment (≥20 cases):

PsoProtect 6-15-22_country

Severity of psoriasis at time of onset of COVID-19 (PGA):

PsoProtect 6-15-22_severity

Hospitalization required due to COVID-19:

PsoProtect 6-15-22_hospital

In addition to demographics, PsoProtect collects the following types of de-identified data:

  • Psoriasis disease characteristics, comorbidities and systemic treatment for psoriasis at onset of COVID-19
  • COVID-19 characteristics and disease course
  • COVID-19 outcome

We encourage clinicians to continue reporting cases of COVID-19 (suspected or confirmed) in psoriasis via the simple online PsoProtect case report form.

*Data are preliminary and include a limited number of cases and should not be used to inform clinical decision making

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Recent Posts

Focus on Psoriasis: A Report from the 2023 American Academy of Dermatology (AAD) Annual Meeting

VIEW
Psoriasis News BMS graphic

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

VIEW

Also Read

Commentary -Tiago Torres
Biologics

Commentary: Trajectories and Prognosis after Discontinuation of Biologics due to Remission in Psoriasis – A Nationwide Cohort Study

The prognosis and maintenance of response after treatment discontinuation following remission lack proper characterization. Real-world data obtained from national registries may provide valuable insights into this clinical issue. Tiago Torres, MD, PhD, provides his expert opinion on a recent study that investigated epidemiological characteristics and disease markers during the first two years following cessation of biologic therapy due to remission in adult patients.

Read More
Tuesday, March 28, 2023

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.
Subscribe